The company was founded in 1972, completed a strategic restructuring in 2021, and became the holding enterprise of the “World Top 500” China Pharmaceutical Group Co., Ltd. As an important part of the Sinopharm Group's modern traditional Chinese medicine sector, the company is committed to inheriting and innovating traditional Chinese medicine and developing modern medicine, mainly through intelligent manufacturing of modern traditional Chinese medicine, and is supplementing it with hemp specialty chemicals. The company is mainly engaged in the production and sale of Chinese and Western medicines, and has a complete pharmaceutical industry chain including pharmaceutical industry, pharmaceutical commerce, and herbal medicine cultivation. The company's main products are agastache zhengqi oral liquid, cefazoxime sodium (iboseling), lofendipine sustained-release tablets (Siweipu), toranisetron hydrochloride injection, Xiaojin tablets, Tianmarin injections, morphine hydrochloride sustained-release tablets (Mifecon), rosiglitazone sodium tablets (Taro), emergency syrup, compound banyan root granules, Tongtian oral solution, sodium chloride injection, sinusitis oral solution, Liuwei Dihuang pills, xanmai orange granules Aromatic gas tablets, Tianjiao, glucose injections, xanliton, digestive enzyme tablets, metoprolol tartrate sustained-release tablets, Xia Sangju granules, cold clean-up granules, Wu Zi Yanzong pills, etc. The company's honors include: “First Prize for National Management Achievements”, No. 1 in the 2017 China Pharmaceutical Top Ten Marketing Cases, and No. 2 in the 2019 China OTC Manufacturing Enterprise Comprehensive Statistics Ranking.
No Data